E-LIB Suche - Ergebnisse für: Trotman, J

1

MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VE..:

Sehn, L. ; Sarkozy, C. ; Song, Y....
Hematological Oncology. 41 (2023) S2 - p. 168-170 , 2023

Link: https://doi.org/10.1002/..

2

MY HODGKIN, MY HEALTH: FEASIBILITY OF A MOBILE APPLICATION ..:

Doo, N. Wong ; Kailanathan, G. ; Tunney, P....
Hematological Oncology. 41 (2023) S2 - p. 680-681 , 2023

Link: https://doi.org/10.1002/..

3

Long‐term efficacy and safety of zanubrutinib (ZANU) in rel..:

Trotman, J. ; Tedeschi, A. ; Hu, B....
Hematological Oncology. 41 (2023) S2 - p. 390-392 , 2023

Link: https://doi.org/10.1002/..

4

ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSL..:

Camus, V. ; Thieblemont, C. ; Gaulard, P....
Hematological Oncology. 41 (2023) S2 - p. 77-78 , 2023

Link: https://doi.org/10.1002/..

5

7P Integration of whole genome sequencing (WGS) into NHS pa..:

Funingana, I.G. ; Trotman, J. ; Ambrose, J....
ESMO Open. 8 (2023) 1 - p. 100861 , 2023

Link: https://doi.org/10.1016/..

6

Predictors of ejection fraction improvement following pulmo..:

Trotman, D ; Rawal, A ; Heckle, M..
The American Journal of the Medical Sciences. 365 (2023) - p. S291 , 2023

Link: https://doi.org/10.1016/..

7

Long term outcome of Peripheral T Cell Lymphomas: 10y follo..:

Civallero, M. ; Advani, R. ; Horwitz, S....
Hematological Oncology. 41 (2023) S2 - p. 491-492 , 2023

Link: https://doi.org/10.1002/..

8

RADIOMICS REFLECTING BOTH TUMOR AND HOST FEATURES IMPROVES ..:

Rebaud, L. ; Capobianco, N. ; Spottiswoode, B....
Hematological Oncology. 41 (2023) S2 - p. 94-95 , 2023

Link: https://doi.org/10.1002/..

9

ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIE..:

Zinzani, P. L. ; Mayer, J. ; Trotman, J....
Hematological Oncology. 41 (2023) S2 - p. 119-121 , 2023

Link: https://doi.org/10.1002/..

10

PEMBROLIZUMAB AS FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELI..:

Dickinson, M. J. ; Trotman, J. ; Berkahn, L....
Hematological Oncology. 41 (2023) S2 - p. 160-161 , 2023

Link: https://doi.org/10.1002/..

11

Final analysis of Australasian Leukaemia & Lymphoma Group N..:

Verner, E. ; Johnston, A. ; Pati, N....
Hematological Oncology. 41 (2023) S2 - p. 426-427 , 2023

Link: https://doi.org/10.1002/..

12

P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RAND..:

Dimopoulos, M. ; Opat, S. ; D'Sa, S....
HemaSphere. 6 (2022) - p. 1048-1049 , 2022

Link: https://doi.org/10.1097/..

13

S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUT..:

Wang, M. L. ; Jurczak, W. ; Jerkeman, M....
HemaSphere. 6 (2022) - p. 110-111 , 2022

Link: https://doi.org/10.1097/..

14

S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) ..:

Zinzani, P. L. ; Mayer, J. ; Auer, R....
HemaSphere. 6 (2022) - p. 106-107 , 2022

Link: https://doi.org/10.1097/..

15

P1261: ALLG LABORATORY SCIENCE STUDY LS21: MOLECULAR CORREL..:

Tatarczuch, M. ; Waltham, M. ; Shortt, J....
HemaSphere. 6 (2022) - p. 1146-1147 , 2022

Link: https://doi.org/10.1097/..